Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial

BACKGROUND: The Phase III OlympiAD study () showed a statistically significant progression-free survival benefit with olaparib versus chemotherapy treatment of physician’s choice (TPC) in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. From this study, we report th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Cancer
Main Authors: ROBSON, Mark, RUDDY, Kathryn J, IM, Seock-Ah, SENKUS, Elżbieta, XU, Binghe, DOMCHEK, Susan M, MASUDA, Norikazu, LI, Wei, TUNG, Nadine, ARMSTRONG, Anne, DELALOGE, Suzette, BANNISTER, Wendy, GOESSL, Carsten, DEGBOE, Arnold, HETTLE, Robert, CONTE, Pierfranco
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6836724/
https://ncbi.nlm.nih.gov/pubmed/31446213
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2019.06.023
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados